Corcept Therapeutics, Inc. (NASDAQ:CORT)

Corcepts lead product korlym is expected to lose exclusivity in 2019.. although that seems concerning.. it isnt.. the small market size in CS will prevent price wars for when generics do enter into the market.. also, Relacorilant, an improved product for CS will EASILY replace Korlym.. Relacorilant will make korlym and any other generic competitors in the space absolete.. Relacorilant is also being explored in clinical trials in combination with abraxane for solid tumors.. Management has expressed that early results have been promising.. If solid tumor data results are as good as managements optimism, we can see CORT fly well above what it is currently worth.. Management are also exploring other combo therapies including korlym in TNBC, CORT125281+xtandi in CRPC.. Also CORT118335 for NASH shouldn't be taken out of the picture.. since their pipeline are all in early stages of development, CORT is considered a speculative play in the favor of longs. the preliminary data of Relacorilant is robust(despite low N) and was executed with the low-end dose.. a higher dose should prove to have better efficacy... Abraxane as a stand alone agent for solid tumors has shown to work in LC,TNBC, CRPC.. the problem with early clinical combo therapies(W/O single agent data), is that sometimes it is hard to figure out whether the net effect is from the combo or from the standalone agent. regardless this confusion of benefit from the combo should boost CORT's share price as market investors are incompetent of realizing the difference between solo efficacy vs combo efficacy.. (see nktr-214).